Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access

NCT06658067 · View on ClinicalTrials.gov ↗

Study Summary

This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.

Interventions

  • DEVICE Continuous Glucose Monitor (CGM)

Study Locations (1)

Connecticut

  • Fair Haven Community Health Care (FHCHC) — New Haven

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2024-11-12
Est. Completion 2026-06
Phase NA

Sponsor

Yale University

1,283 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06658067

The ClinicalTrials.gov registry entry for NCT06658067 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,283 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention — of which Continuous Glucose Monitor (CGM) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06658067 reports 1 study location spanning 1 distinct geographic area — top geographies include Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06658067 about?

NCT06658067 is a clinical study titled "Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access". This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.

What is the current status of trial NCT06658067?

This trial is currently recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2024-11-12. Estimated completion is 2026-06.

What conditions does trial NCT06658067 study?

This clinical trial studies the following conditions: Diabetes, Type 2 Diabetes, Type 2 Diabetes Mellitus - Poor Control. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06658067?

The interventions under investigation include: Continuous Glucose Monitor (CGM) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06658067?

This trial is sponsored by Yale University, which has 1,283 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06658067 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial